comprehensive -WSS

comprehensive

author：entertainment 2025-10-02 22:56:21 - browse：27393

What’s a radiopharmaceutical? What does it mean to be Zepbound? And who’s to blame for a biotech blow-up?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make them. We also discuss the approval of Eli Lilly’s curiously named treatment for obesity, the latest implosion for a promising biotech company, and some news in the world of shareholder activism.

For more on what we cover, here’s the radiopharmaceuticals story; here’s the news on Lilly; here’s more on Ventyx Biosciences; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： How one medical school became remarkably diverse
Next article： Yancopoulos of Regeneron works to expand Dupixent success

WSS

Eli Lilly to pay $200M for Beam’s stake in gene

Yancopoulos of Regeneron works to expand Dupixent success

Readout Newsletter: XBI biotech index, Akero Therapeutics

WHO may add ‘noma' to its list of neglected tropical diseases

Diabetes management: Digital health tools fall short, study says

Diversifying clinical trials isn't enough to close racial gaps: study

knowledge

comprehensive

knowledge

In age of alternative facts, a scholarly course on calling out crap

U.K. officials, researchers try to ease path for bespoke genetic treatments

Continuity nursing helped my family in our darkest PICU moments

Cassava reveals details — and problems — with Alzheimer's study

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The FDA weighs the risks of candy

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare Advantage insurers pressure Biden for bigger payments

Hepatitis C has a cure — but many Americans still lack access to it

'Patient friction coefficient' can gauge a clinical trial's patient burden

focus

Yancopoulos of Regeneron works to expand Dupixent success

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

First Opinion Podcast: How to protect health care in times of war

Pfizer, Moderna say biotech, pharma drug development is a sprint

Testing for cancer recurrence creates a new limbo for patients

WHO may add ‘noma' to its list of neglected tropical diseases

focus

hotspot

explore

leisure time